Start practising

PassthePSA › PSA exam guide

PSA exam guide

The Prescribing Safety Assessment, section by section

A guide to the UK Prescribing Safety Assessment: how the paper is built, what each of its eight sections asks you to do, how it is marked, and how to prepare. The exam's figures are the assessment provider's; the advice is ours.

questions
60
marks
200
minutes
120
sections
8
Start practising →Every question free, no card

The exam at a glance

FormatOnline, 60 items in eight sections, 200 marks
Time120 minutes: on average 2 minutes an item, or 36 seconds a mark
ReferenceThe online BNF and BNF for Children are available inside the assessment, and scoring follows the versions current at the time of the assessment. The UK Foundation Programme adds that paper copies can be allowed but may not contain the latest advice, and that no notes may be made in them.
Answer stylesWritten prescriptions, single best answers, ticks against prescriptions on a drug chart, and numbers in a stated unit
Pass markSet for each paper by the provider through standard setting; not a fixed percentage and not published in advance
Who sits itFinal-year medical students, and foundation doctors who have not yet passed (a pass is needed to complete F1)
DatesPublished by the provider each academic year; medical schools register their own students. Dates, format and resits, with sources

Sources: prescribingsafetyassessment.ac.uk and the UK Foundation Programme. The official site is authoritative; read it before any sitting.

The blueprint: where the 200 marks are

The sections are not equal. Prescribing is 8 items at 10 marks: 80 marks, 40% of the paper, and more than the next three sections combined. Revision time and pace should follow the marks.

  1. Prescribing8 items · 10 marks each80 marks · 40%
  2. Prescription Review8 items · 4 marks each32 marks · 16%
  3. Planning Management8 items · 2 marks each16 marks · 8%
  4. Communicating Information6 items · 2 marks each12 marks · 6%
  5. Calculation Skills8 items · 2 marks each16 marks · 8%
  6. Adverse Drug Reactions8 items · 2 marks each16 marks · 8%
  7. Drug Monitoring8 items · 2 marks each16 marks · 8%
  8. Data Interpretation6 items · 2 marks each12 marks · 6%

Bars are drawn to scale by marks. Section names, items and marks: the official PSA blueprint at prescribingsafetyassessment.ac.uk; the 5 + 5 split of a prescribing item: the PSA Item Writing Manual (PDF).

How items are answered

The PSA is not a pharmacology multiple-choice paper. Three of its item styles ask you to do something other than pick an option: write a prescription, tick prescriptions on a drug chart, or type a number in a stated unit. Practice that only uses single-best-answer questions leaves those tasks untrained.

SectionWhat the exam asks you to doOn PassthePSA
PrescribingWrite one prescription on the chart: medicine, dose, route, frequencyThe same chart. Marked in two halves, component by component, with partial credit and the marking tier shown
Prescription ReviewTick the responsible prescription(s) on a drug chartThe same chart with a tick column per question part
Planning ManagementSingle best answer from fiveSingle best answer in the exam's layout, explanation cites the BNF pathway
Communicating InformationSingle best answer from fiveSingle best answer in the exam's layout
Calculation SkillsType a number in the stated unitThe same numeric box with the unit shown, working in the explanation
Adverse Drug ReactionsSingle best answer from a chart or option listSingle best answer in the exam's layout
Drug MonitoringSingle best answer from fiveSingle best answer in the exam's layout
Data InterpretationSingle best answer on printed results with reference rangesSingle best answer with the results printed as the exam prints them

PassthePSA's practice is designed to reflect the PSA's format, structure and marking closely. It is independent: not affiliated with or endorsed by the assessment provider.

The eight sections

The same five questions for every section, so they can be compared at a glance. Each name opens the full section guide, with the method, the BNF route, the traps and worked examples.

Prescribing

8 items · 10 marks each · 80 marks

You do
Write one prescription on the chart: medicine, dose, route, frequency
It tests
Choosing the right drug, then writing it safely
Strategy
Name the indication → Choose the class, then the drug → Find the dose under the right indication → Apply the patient → Write it as the chart needs it
Pitfalls
Volume instead of dose; wrong indication, wrong dose; right drug, wrong section of the chart
In the BNF
Indications and dose, renal and hepatic impairment, contra-indications

Section guide Practise Revision note

Prescription Review

8 items · 4 marks each · 32 marks

You do
Tick the responsible prescription(s) on a drug chart
It tests
Finding the culprit drug in a realistic chart
Strategy
Read the problem first → Find what changed → Ask the timing question → Check the pair → Confirm, then tick
Pitfalls
The drug that treats it; plausible but the timing is wrong; two answers when one is asked
In the BNF
Interactions, side-effects, contra-indications, renal impairment

Section guide Practise Revision note

Planning Management

8 items · 2 marks each · 16 marks

You do
Single best answer from five
It tests
Choosing the correct next treatment step
Strategy
Identify the problem → Decide the urgency → Find the first-line pathway → Apply the modifiers → Check it is the next step
Pitfalls
Second-line too early; ignoring the modifier; treating the number
In the BNF
Treatment summaries, then the relevant monograph

Section guide Practise

Communicating Information

6 items · 2 marks each · 12 marks

You do
Single best answer from five
It tests
Prioritising the safety-critical advice
Strategy
Name the worst realistic harm → Ask what the patient must do or avoid to prevent it → Check the drug's specific warnings → Rank the remaining options → Choose one
Pitfalls
The useful over the vital; generic advice; forgetting the patient
In the BNF
Patient and carer advice, important safety information, warnings
Name
The official PSA FAQ describes this section as providing information about medicines.

Section guide Practise Revision note

Calculation Skills

8 items · 2 marks each · 16 marks

You do
Type a number in the stated unit
It tests
Dose, volume, rate and conversion arithmetic
Strategy
Read the units → Identify the target → Calculate the dose → Convert to what is given → Check the magnitude
Pitfalls
Daily versus single dose; micrograms and milligrams; percent means g per 100 mL
In the BNF
Usually the question supplies the numbers; the BNF confirms the dose where required

Section guide Practise Revision note

Adverse Drug Reactions

8 items · 2 marks each · 16 marks

You do
Single best answer from a chart or option list
It tests
Attributing a presentation to a medicine
Strategy
Timing → Plausibility → Competing causes → Interactions → Action
Pitfalls
Blaming the newest drug automatically; can cause is not did cause; missing the interaction
In the BNF
Side-effects, contra-indications, interactions

Section guide Practise Revision note

Drug Monitoring

8 items · 2 marks each · 16 marks

You do
Single best answer from five
It tests
Knowing what to measure, when, and what to do with it
Strategy
Identify the drug and its risk → Classify the monitoring → Find the timing → Interpret the result → Decide the action
Pitfalls
Right test, wrong time; repeating what is already known; confusing the four kinds
In the BNF
Monitoring requirements in the monograph

Section guide Practise Revision note

Data Interpretation

6 items · 2 marks each · 12 marks

You do
Single best answer on printed results with reference ranges
It tests
Acting on results: continue, adjust, hold or stop
Strategy
Spot the abnormality → Decide whether it is significant → Link it to a medicine → Find the action threshold → Continue, adjust, hold or stop
Pitfalls
Reacting to noise; adjusting the wrong drug; stopping when reducing is asked
In the BNF
Monitoring requirements, renal impairment, dose adjustment thresholds

Section guide Practise Revision note

Video guide: all 8 sections

Each section worked through on the exam interface, with the BNF open: about ten minutes a section. Each video is also at the top of its section's guide.

PSA Prescribing: How to Score 10/10 (2 Worked Examples) | Section 1 of 810 minWatch on YouTube
PSA Prescription Review: Spot the Wrong Drug (2 Worked Examples) | Section 2 of 89 minWatch on YouTube
PSA Planning Management: 3 Worked Examples and the Traps | Section 3 of 810 minWatch on YouTube
PSA Providing Information: Missed Doses, Warning Signs, Timing | Section 4 of 89 minWatch on YouTube
PSA Calculation Skills: 3 Worked Examples (Doses, Infusion Rates, %) | Section 5 of 89 minWatch on YouTube
PSA Adverse Drug Reactions: Culprit, Interaction, Management | Section 6 of 89 minWatch on YouTube
PSA Drug Monitoring: Lithium, Digoxin and Phenytoin (Worked Examples) | Section 7 of 89 minWatch on YouTube
PSA Data Interpretation: Read the Patient, Not Just the Number | Section 8 of 810 minWatch on YouTube

More on the PassthePSA YouTube channel.

Time

Two minutes an item is the average, not the rule. At 36 seconds a mark, a 10-mark prescribing item has earned six minutes and a 2-mark item just over one.

ItemsMarks eachTime at exam paceIn the paper
Prescribing10 marks6 minutes per item8 items, about 48 minutes
Prescription Review4 marks2 min 24 s per item8 items, about 19 minutes
Planning Management, Communicating Information, Calculation Skills, Adverse Drug Reactions, Drug Monitoring, Data Interpretation2 marks1 min 12 s per item44 items, about 53 minutes
  • Check the clock against marks done, not items done. Candidates who run out of time have usually spent prescribing time on cheap items early in the paper.
  • Answer, flag, move. If a lookup is not converging inside a minute, enter your best answer, flag it and come back.
  • Keep the last ten minutes for flagged items, and for reading every prescription you wrote once more, as a nurse would.

Marking

ItemsMarksHow they are marked
Prescribing10Two independent halves: 5 marks for the choice of drug, 5 for the dose, route and frequency written. A right drug at a wrong dose keeps half the item.
Prescription Review4Ticks against prescriptions on a chart. Read whether each part wants one prescription or two.
The other six sections2Single best answer or a number in a stated unit. Most of these items are all or nothing.
The paper200The pass standard is set for each paper by the assessment provider and is not a fixed percentage, so practice scores are best read as a trend.

Common mistakes

MistakeInstead
Revising drugs instead of the examMemorising doses is slow and unnecessary. The BNF is open. Practise finding, not recalling.
Never practising on the formPrescribing is 80 marks and is written, not chosen. Choosing from options does not train it.
Ignoring the clock until the mockPace is a skill. Build it early with short timed sets.
Reading explanations only when wrongA right answer by the wrong reasoning fails next time. Read them all.
Skipping the unitsCalculation marks are lost to units, not arithmetic.
Treating the pass mark as a targetIt is set per paper and unknown in advance. Aim well above any figure you have heard.

Using the BNF

The BNF is open throughout. The skill is not knowing it; it is knowing which heading answers which question, and getting there in seconds. Do the lookup even when you are sure: the PSA punishes remembered doses, and confirming one takes seconds.

Question→Which BNF heading?→Search generic or condition→Jump to the heading→Apply the patient→Answer

The BNF guide maps where each kind of answer lives, with timed lookups and navigation challenges.

Preparing

StageWhat to do
Learn the formatRead the section guides. Know the answer styles and where the marks are before you practise.
Practise untimed, by sectionGet the method right with the BNF open and no clock. Read every explanation, especially on the ones you got right by luck.
Find the weak sectionsAccuracy per section tells you where the marks are leaking. Drill those, not the ones you enjoy.
Practise timedShort timed sets at exam pace, to find out where the time goes.
Sit full papersSixty items in two hours, under the rules. Then review every prescription you wrote.
Review the errorsThe question you got wrong and understood is worth more than ten you got right. Redo them a week later.

Full mock papers

Each of the 11 mock papers is 60 items and 200 marks in 120 minutes, in the official section proportions. The clock runs at exam pace, items can be flagged and revisited, and every item is marked as the exam marks it, with a section breakdown afterwards. How the mock papers work.

Worked examples

20 real questions from the bank, from every section. Choose a section, open an example, work it with the BNF, then reveal the answer and the explanation. These are for learning; the practice questions use the exam's own layout.

Prescribing · PWS-87 · 10 marksThromboprophylaxis for a 58-year-old admitted with pneumoniaWrite a prescription for the ONE drug that is most appropriate to reduce his risk of venous thromboembolism during this admission.

Prescribing · PWS-87 · 10 marks · easy

Case

A 58-year-old man is admitted to the acute medical unit with community-acquired pneumonia. He is breathless walking to the bathroom and is expected to spend most of the next few days in bed. The admission venous thromboembolism risk assessment scores him at increased risk of thrombosis and low risk of bleeding, and the consultant asks for pharmacological thromboprophylaxis to be prescribed alongside the antibiotic. He has never had a thrombosis and has never taken an anticoagulant.

PMH: Type 2 diabetes mellitus; hypertension.

DH: metformin 500 mg PO twice daily (12-hrly); amlodipine 5 mg PO daily; doxycycline 200 mg PO today, then 100 mg PO once daily (started today for the pneumonia; atypical pneumonia suspected). No known drug allergies.

SH: non-smoker; drinks 8 units of alcohol a week; delivery driver.

On examination: Temperature 38.1°C, HR 96/min and regular, BP 128/76 mmHg, RR 22/min, O2 sat 94% breathing air. Weight 82 kg. Right basal crackles with dullness to percussion. No calf swelling or tenderness. No rash, no bruising, no bleeding.

Investigations: Na 136 mmol/L (135–145) K 4.2 mmol/L (3.5–5.3) Urea 6.2 mmol/L (2.5–7.8) Creatinine 76 µmol/L (60–120) Hb 148 g/L (130–180) WCC 13.6 ×10⁹/L (4.0–11.0) Platelets 322 ×10⁹/L (150–400) CRP 118 mg/L (<5) Chest X-ray: right lower lobe consolidation

Question

Write a prescription for the ONE drug that is most appropriate to reduce his risk of venous thromboembolism during this admission.

(use the hospital 'regular medicines' prescription form provided)

Your answer: one written prescription, giving the medicine, dose, route and frequency.

Show the answer and markingHide the answer
Model answer

enoxaparin sodium 40 mg/0.4 mL pre-filled syringe (Clexane®) · 40 mg · subcutaneous (SC) · once daily

Marks

5 for the drug choice, 5 for the written prescription (dose, route, frequency).

Also credited

enoxaparin; enoxaparin sodium; Clexane; Inhixa; dalteparin; dalteparin sodium; Fragmin

Drug choice

An acutely ill medical inpatient whose mobility has just collapsed is exactly who pharmacological thromboprophylaxis is for, and the risk assessment printed with the case has already made the decision to treat — increased thrombosis risk, low bleeding risk. The UK answer is a low molecular weight heparin, and the BNF doses two of them for this precise indication: enoxaparin 40 mg every 24 hours, dalteparin 5000 units every 24 hours, both subcutaneous. Either earns full marks. Fondaparinux 2.5 mg once daily is a licensed, NICE-listed alternative and loses one mark on drug choice only. Tinzaparin is the trap inside the class: its prophylaxis licences are surgical (3500 units general surgery, 4500 units orthopaedic) and it has no medical-patient dose to write. Unfractionated heparin 5000 units twice daily is kept for patients who cannot have a low molecular weight heparin — severe renal impairment, mainly — and this man's creatinine clearance is about 109 mL/minute. The direct oral anticoagulants fail on licence: rivaroxaban and apixaban cover prophylaxis only after hip or knee replacement, and trials of extended oral prophylaxis in medical patients bought extra bleeding for no net benefit. Aspirin is an antiplatelet, and NICE NG89 says in terms not to use it for this purpose.

Explanation

His doxycycline does not change the choice. The BNF interaction checker flags a theoretical risk of hepatotoxicity when doxycycline is given with HIGH-DOSE enoxaparin or dalteparin; it attaches the same flag to dozens of drugs, including paracetamol. A 40 mg prophylactic dose of enoxaparin is the lowest adult dose, not a high dose, and unfractionated heparin carries an unqualified version of the same warning, so switching would not avoid it.

Dose, route and frequency

The dose is 40 mg — or, as the Clexane SmPC itself writes it, 4,000 IU — subcutaneously once daily. The number that catches people is 20. Twenty milligrams is a real enoxaparin dose twice over: the moderate-risk surgical dose, and the prophylaxis dose when creatinine clearance falls to 15–30 mL/minute. Neither applies to a 58-year-old with a creatinine of 76 µmol/L, and half-dose prophylaxis in normal renal function is under-protection. In the other direction, 1 mg/kg twice daily and 1.5 mg/kg once daily are TREATMENT doses — for a thrombosis he does not have — and score nothing for the prescription half, as does 40 mg written twice daily, which is the same 80 mg a day by another route. Check the platelet count before starting any heparin (his is 322 ×10⁹/L, printed) and remember the count needs rechecking if he is still on it after 4 days.

Credited answers

enoxaparin sodium 40 mg/0.4 mL pre-filled syringe (Clexane®/Inhixa®) — 40 mg (4,000 units), subcutaneous (SC), once daily. Full marks. dalteparin sodium 5000 units/0.2 mL (Fragmin®) — 5000 units, subcutaneous (SC), once daily. Full marks. Also credited for drug choice: fondaparinux 2.5 mg SC once daily (4 + 5); unfractionated heparin 5000 units SC twice daily (2 + 5); tinzaparin (3 + 0); 'low molecular weight heparin' unnamed (2 + 0). rivaroxaban, apixaban, warfarin, aspirin — 0/10. (BNF, enoxaparin sodium and dalteparin sodium monographs, and Clexane SmPC, all read 22 August 2026.)

How this item is marked

Every answer is matched to a marking tier. These are the first rows of this item's real scheme (33 tiers in total).

MedicineDose and routeMarksMarking note
enoxaparin40 mg · subcutaneous (SC)10 / 10optimal. BNF, prophylaxis of deep-vein thrombosis in medical patients: 'By subcutaneous injection, Adult: 40 mg every 24 hours.' Normal renal function (Cockcrof…
enoxaparin4000 units · subcutaneous (SC)10 / 10the same dose written in units — the Clexane SmPC's own spelling is '4,000 IU (40 mg) once daily'.
Clexane40 mg · subcutaneous (SC)10 / 10the same prescription under the brand name; biological medicines are in any case prescribed by brand. Credited identically.
Inhixa40 mg · subcutaneous (SC)10 / 10the biosimilar brand. Credited identically.
dalteparin5000 units · subcutaneous (SC)10 / 10the co-equal alternative: BNF, prophylaxis of deep-vein thrombosis in medical patients, 'By subcutaneous injection, Adult: 5000 units every 24 hours.' Any UK tr…
Fragmin5000 units · subcutaneous (SC)10 / 10dalteparin under its brand name. Credited identically.
enoxaparin20 mg · subcutaneous (SC)6 / 10the renal-impairment dose (creatinine clearance 15–30 mL/minute) or the moderate-risk surgical dose, given to a man whose creatinine clearance is about 109 mL/m…
enoxaparin2000 units · subcutaneous (SC)6 / 10the same under-dose written in units (2,000 IU = 20 mg). Deduct 4.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question PWS-87 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Prescribing · PWS-88 · 10 marksA 66-year-old with chronic kidney disease, weakness and palpitations after a new antibioticWrite a prescription for the ONE drug that is most appropriate to give first.

Prescribing · PWS-88 · 10 marks · medium

Case

A 66-year-old man is brought to the emergency department with two days of worsening weakness and palpitations. He has chronic kidney disease, and three days ago his general practitioner started an antibiotic for a urinary tract infection. He is on a cardiac monitor in the resuscitation area with resuscitation staff present.

PMH: Chronic kidney disease; hypertension; benign prostatic enlargement.

DH: ramipril 5 mg PO daily; trimethoprim 200 mg PO twice daily (12-hrly), day 3 of 7; atorvastatin 20 mg PO nightly; tamsulosin 400 micrograms PO daily. No known drug allergies.

SH: retired; lives with his wife; non-smoker.

On examination: Temperature 36.9°C, HR 88/min and regular, BP 138/84 mmHg, RR 16/min, O2 sat 97% breathing air. Alert and orientated. Proximal muscle weakness in both legs; reflexes present. Chest clear, JVP not raised, no oedema. Abdomen soft; bladder not palpable. A 22-gauge cannula is sited in the back of the left hand and flushes easily. He is attached to a cardiac monitor.

Investigations: Na 134 mmol/L (135–145) K 7.1 mmol/L (3.5–5.3) Bicarbonate 17 mmol/L (22–29) Urea 21.4 mmol/L (2.5–7.8) Creatinine 187 µmol/L (60–120), eGFR 34 mL/min/1.73 m² Glucose 6.8 mmol/L (4.0–7.8) 12-lead ECG: peaked T waves in the chest leads, flattened P waves, QRS duration 136 ms

Question

Write a prescription for the ONE drug that is most appropriate to give first.

(use the once-only section of the chart)

Your answer: one written prescription, giving the medicine, dose, route and frequency.

Show the answer and markingHide the answer
Model answer

calcium gluconate 10% solution for injection · 30 mL · intravenous (IV) · once only, given by slow intravenous injection over 10 minutes; repeat if no improvement in the ECG within 5–10 minutes

Marks

5 for the drug choice, 5 for the written prescription (dose, route, frequency).

Also credited

calcium gluconate; calcium chloride; cal gluconate; ca gluconate

Drug choice

Severe hyperkalaemia with ECG changes is two problems in sequence, and the marks here are for knowing the sequence. Problem one is that his myocardium is about to arrest: peaked T waves, flattened P waves and a QRS of 136 ms are the walk to a sine wave. Intravenous calcium fixes none of the potassium and all of the immediate danger — it re-stabilises the membrane within minutes, which is why the BNF's instruction for ECG-change hyperkalaemia is calcium first, with the ECG rechecked at 5–10 minutes and the dose repeated if the trace has not improved. Problem two is the potassium itself, and that is where insulin comes in: 10 units of soluble insulin with 25 g of glucose over 5–30 minutes drives potassium into cells from about 15 minutes. Prescribed FIRST, insulin–glucose leaves the myocardium bare for exactly the quarter of an hour in which this ECG is at its most dangerous — which is why it collects partial credit for drug knowledge and nothing for the prescription. Salbutamol is an adjunct to that second step; the binders (sodium zirconium cyclosilicate, patiromer, the old resin) act over hours in the gut and belong to the non-emergency presentation; bicarbonate treats the acidaemia, not the emergency; furosemide is an afterthought for later.

Dose, route and frequency

The dose question is the salt question, and the MHRA wrote to every UK prescriber about it in June 2023 after deaths from getting it wrong. Thirty millilitres of calcium GLUCONATE 10% provides approximately 6.8 mmol of calcium — the same calcium as TEN millilitres of calcium CHLORIDE 10%. Two traps follow. First, the 10 mL ampoule of gluconate — the hypocalcaemia dose everyone has seen given — delivers a third of what this ECG needs, and underdosing is the specific error the MHRA advice names. Second, 30 mL written against calcium chloride is a threefold calcium overdose. Give the gluconate by slow intravenous injection over 10 minutes, into a monitored patient, and recheck the ECG at 5–10 minutes: the effect lasts only 30–60 minutes, so a repeat is often needed. Calcium chloride at its correct 10 mL dose loses a single mark here: the BNF prefers gluconate outside cardiac arrest, and chloride is the more irritant salt to push through a 22-gauge cannula in the back of a hand.

Explanation

Also part of the plan, though not marked in the boxes: insulin–glucose immediately after the calcium, a potassium recheck, holding the ramipril and trimethoprim, and senior renal input at an eGFR of 34.

Credited answers

calcium gluconate 10% solution for injection — 30 mL (approximately 6.8 mmol), intravenous (IV) by slow injection over 10 minutes, once only, repeat if the ECG has not improved at 5–10 minutes. Full marks. Fifteen to 29 mL: 5 + 1. Ten millilitres: 5 + 0. Above 30 mL: 5 + 0. calcium chloride 10% — 10 mL (1 g) IV once only: 5 + 4. Thirty millilitres of the chloride: 5 + 0. insulin–glucose (any spelling) — 2 + 0. 'calcium' with no salt — 2 + 0. salbutamol — 1 + 0. sodium zirconium cyclosilicate, patiromer, calcium polystyrene sulfonate, sodium bicarbonate, furosemide — 0/10. (BNF hyperkalaemia treatment summary and calcium gluconate monograph, including the MHRA/CHM advice of June 2023, read 22 August 2026.)

How this item is marked

Every answer is matched to a marking tier. These are the first rows of this item's real scheme (38 tiers in total).

MedicineDose and routeMarksMarking note
calcium gluconate30 mL · intravenous (IV)10 / 10optimal. BNF, acute severe hyperkalaemia: 'By slow intravenous injection, Adult: 30 mL for 1 dose, calcium gluconate 10% (providing approximately 6.8 mmol of ca…
calcium gluconate30 mL · intravenous (IV)10 / 10the same prescription with the administration time written in the frequency box, which is where a once-only chart's rate instruction often lands. '10 minutes', …
calcium gluconate3 g · intravenous (IV)10 / 10the same dose in grams: 30 mL of a 10% solution is 3 g (BNF: calcium gluconate 1 g contains Ca2+ 2.23 mmol; 3 × 2.23 ≈ 6.7 mmol, the monograph's 'approximately …
calcium gluconate6.8 mmol · intravenous (IV)10 / 10the same dose written as millimoles of calcium, the MHRA advice's own figure. Credited identically.
calcium gluconate3 ampoules · intravenous (IV)10 / 10three 10 mL ampoules of the 10% solution are 30 mL. Credited identically.
calcium gluconate15-29 mL · intravenous (IV)6 / 10between the hypocalcaemia dose and the hyperkalaemia dose — most often a remembered '10–20 mL'. Under the 6.8 mmol the ECG needs, on a warning the MHRA issued p…
calcium gluconate1.5-2.9 g · intravenous (IV)6 / 10the same intermediate underdose written in grams (15–29 mL of 10%). Deduct 4.
calcium gluconate1-14 mL · intravenous (IV)5 / 10the classic error the MHRA's June 2023 advice exists for: the 10 mL hypocalcaemia ampoule given for hyperkalaemia, a third of the calcium the ECG needs. Right d…

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question PWS-88 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Prescribing · PWS-89 · 10 marksA 73-year-old on warfarin with haematemesis and melaenaWrite a prescription for the ONE additional drug that is most appropriate to reverse his anticoagulation now.

Prescribing · PWS-89 · 10 marks · hard

Case

A 73-year-old man is brought to the emergency department after vomiting fresh blood twice this evening, having passed black tarry stools since this morning. He takes warfarin for atrial fibrillation, and 5 days ago his dentist started an antibiotic for a dental abscess. He is in the resuscitation area: the major haemorrhage protocol has been activated, the transfusion laboratory — which confirms full stocks — has issued red cells, and the first unit is running. Phytomenadione 5 mg has been given by slow intravenous injection and tonight's warfarin is withheld.

PMH: atrial fibrillation; hypertension; dental abscess (5 days ago).

DH: warfarin sodium PO daily (target INR 2.5, usual maintenance 4 mg); metronidazole 400 mg PO three times daily (8-hrly), day 5 of 7 (dental abscess); ramipril 5 mg PO daily; atorvastatin 20 mg PO nightly. No known drug allergies.

SH: retired plumber; lives with his wife; drinks 4 units of alcohol a week; non-smoker.

On examination: Temperature 36.4°C, HR 118/min and irregularly irregular, BP 92/58 mmHg, RR 22/min, O2 sat 96% breathing air. Weight 80 kg. Pale, cool peripheries with a prolonged capillary refill; alert and answering questions. Epigastric tenderness; melaena on rectal examination. Two large-bore cannulae are sited; the first unit of red cells is running through one of them.

Investigations: Hb 72 g/L (130–180) Platelets 256 ×10⁹/L (150–400) Na 138 mmol/L (135–145), K 4.4 mmol/L (3.5–5.3) Urea 14.2 mmol/L (2.5–7.8), creatinine 102 µmol/L (60–120) INR 6.8 (target 2.5) Cross-match: 2 units of red cells issued, further units available

Question

Write a prescription for the ONE additional drug that is most appropriate to reverse his anticoagulation now.

(use the once-only section of the chart)

Your answer: one written prescription, giving the medicine, dose, route and frequency.

Show the answer and markingHide the answer
Model answer

dried prothrombin complex (four-factor prothrombin complex concentrate, Beriplex® P/N) · 4000 units (50 units/kg) · intravenous (IV) infusion · once only

Marks

5 for the drug choice, 5 for the written prescription (dose, route, frequency).

Also credited

dried prothrombin complex; prothrombin complex concentrate; prothrombin complex; PCC; Beriplex; Octaplex

Drug choice

Warfarin reversal in major bleeding is a two-drug algorithm, and the marks here are for the drug that works tonight. The BNF's haemorrhage guidance reads: 'Major bleeding—stop warfarin sodium; give phytomenadione (vitamin K1) by slow intravenous injection; give prothrombin complex (factors II, VII, IX, and X); if prothrombin complex unavailable, fresh frozen plasma can be given but is less effective; recombinant factor VIIa is not recommended for emergency anticoagulation reversal' (BNF, oral anticoagulants treatment summary, read 22 August 2026). The phytomenadione has been given — it switches factor synthesis back on, but synthesis takes hours this haematemesis will not wait for. Dried prothrombin complex IS the missing factors, in a vial: II, VII, IX and X, reconstituted and infused in minutes. Fresh frozen plasma earns partial credit only, because the BNF's condition for it — prothrombin complex unavailable — is printed false: the laboratory is fully stocked, and plasma is slower (thawing), bulkier (a volume load in a shocked man) and weaker (dilute factors). Writing phytomenadione again earns a single mark for knowing the algorithm's other arm: it is already running and the question asks for the ONE additional drug. The zeros are the wrong-patient reversal shelf: idarucizumab reverses dabigatran, andexanet alfa reverses apixaban and rivaroxaban, protamine reverses heparin, and recombinant factor VIIa is the product the BNF's algorithm itself rules out by name.

Dose, route and frequency

The BNF dose is 25–50 units/kg by intravenous infusion (prothrombin complex monograph, read 22 August 2026) — for this man's printed 80 kg, 2000–4000 units; the model answer takes 50 units/kg = 4000 units, because the Beriplex SmPC's own INR-banded table gives 50 IU/kg for a pre-treatment INR above 6. ('IU' is the SmPC's notation. On a UK prescription 'IU' and 'U' are never written — they are misread as 0 or 10 — and score zero for this half; write 'units' or 'international units' in full.)0 (capped at 5000 IU in patients over 100 kg) and his INR is 6.8. Write 'units'. Any dose from 25 to 50 units/kg sits inside the BNF band and earns full marks. The characteristic dose error is writing a VIAL as a dose: prothrombin complex comes in 500-unit and 1000-unit vials, and 500 units is about 6 units/kg for this man — a token. Under-dosing at 10–24 units/kg loses 4 of the 5 prescription marks; anything above 50 units/kg over-doses a prothrombotic product in a man with atrial fibrillation and scores nothing for the prescription half.

Explanation

Also part of the plan, though not marked in the boxes: urgent endoscopy once resuscitated, a recheck of the INR after the infusion, stopping the metronidazole interaction review (BNF: 'Metronidazole increases the anticoagulant effect of Warfarin', severity severe), and a documented plan for if and when anticoagulation restarts.

Credited answers

dried prothrombin complex (prothrombin complex concentrate / PCC / Beriplex® P/N / Octaplex®) — 25–50 units/kg (2000–4000 units for 80 kg), intravenous infusion, once only. Full marks. 10–24 units/kg (800–1999 units): 5 + 1. Token doses and doses above 50 units/kg: 5 + 0. fresh frozen plasma (FFP / Octaplas®) — 2 + 0. phytomenadione (vitamin K) — 1 + 0. tranexamic acid — 1 + 0. recombinant factor VIIa, idarucizumab, andexanet alfa, protamine, or any 'PCC or FFP' hedge — 0/10. (BNF oral anticoagulants treatment summary, prothrombin complex and phytomenadione monographs, and metronidazole interactions page, all read 22 August 2026; Beriplex P/N SmPC read the same day.)

How this item is marked

Every answer is matched to a marking tier. These are the first rows of this item's real scheme (65 tiers in total).

MedicineDose and routeMarksMarking note
dried prothrombin complex25-50 units/kg · intravenous (IV)10 / 10optimal, written per kilogram. BNF, prothrombin complex monograph: 'Major bleeding in patients on warfarin [following phytomenadione] … By intravenous infusion,…
dried prothrombin complex2000-4000 units · intravenous (IV)10 / 10the same dose resolved against his printed 80 kg: 25 × 80 = 2000 units, 50 × 80 = 4000 units. Credited identically.
dried prothrombin complex10-24 units/kg · intravenous (IV)6 / 10below the BNF's 25 units/kg floor — a partial factor replacement that under-corrects an INR of 6.8. Deduct 4 rather than zero: the drug and route are right and …
dried prothrombin complex800-1999 units · intravenous (IV)6 / 10the same underdose written in absolute units (10–24.9 units/kg at 80 kg). Deduct 4.
dried prothrombin complex1-9 units/kg · intravenous (IV)5 / 10a token dose — a fraction of any effective regimen. Right drug, failed prescription half.
dried prothrombin complex1-799 units · intravenous (IV)5 / 10the remembered vial size (500 or 1000-unit vials exist) written as the dose: under 10 units/kg for this 80 kg man. Zero for the prescription half.
dried prothrombin complex51-150 units/kg · intravenous (IV)5 / 10above the 50 units/kg ceiling of a prothrombotic product given to a man with atrial fibrillation. Zero for the prescription half.
dried prothrombin complex4001-12000 units · intravenous (IV)5 / 10the same overdose in absolute units. Zero for the prescription half.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question PWS-89 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Prescription Review · REV-83 · 4 marksAn 84-year-old with two weeks of confusion, a dry mouth and constipationQuestion A: Select the ONE prescription most likely to have precipitated her confusion. (mark it with a tick in column A) Question B: Select the ONE OTHER prescription contributing to her anticholinergic burden.

Prescription Review · REV-83 · 4 marks · easy

Case

An 84-year-old woman is brought to the frailty assessment unit by her daughter, who says her mother has been muddled for about 2 weeks — losing the thread of conversations, drowsy in the afternoons, and constantly sipping water because her mouth is dry. She has opened her bowels twice in the past week, passing hard stools despite her usual laxative. Three weeks ago her general practitioner started a tablet for nausea, which has settled. Her bladder symptoms of urgency have been treated with the same tablet for 4 years. Her current prescriptions are shown.

PMH: Urge urinary incontinence; hypertension; hypercholesterolaemia; hypothyroidism; chronic constipation; osteoarthritis of the knees.

DH: As charted; no over-the-counter or herbal preparations; no known drug allergies.

SH: Lives alone with daily family visits; lifelong non-smoker; no alcohol.

On examination: Temperature 36.9°C, HR 96/min regular, BP 142/84 mmHg, RR 16/min, O2 sat 96% breathing air. Drowsy but rousable; inattentive, with an abbreviated mental test score of 6/10 against 9/10 documented at a clinic visit 4 months ago. Oral mucosa dry. Abdomen soft with palpable stool in the left iliac fossa; the bladder is palpable above the pubis after she has passed urine. No focal neurology.

Investigations: Na 139 mmol/L (133–146) K 4.2 mmol/L (3.5–5.3) Urea 6.0 mmol/L (2.5–7.8) Cr 74 µmol/L (45–90) eGFR 69 mL/min/1.73 m² (>60) Glucose 5.4 mmol/L (4.0–7.8) TSH 2.1 mU/L (0.3–4.2) CRP 4 mg/L (<5) Urine dipstick: negative for nitrites, leucocytes and blood

Question

Question A: Select the ONE prescription most likely to have precipitated her confusion. (mark it with a tick in column A)

Question B: Select the ONE OTHER prescription contributing to her anticholinergic burden.

(mark it with a tick in column B)

Current prescriptions

  • amlodipine
  • atorvastatin
  • cyclizine
  • levothyroxine
  • paracetamol
  • senna
  • tolterodine

Tick one prescription in each column: A, B.

Show the answer and markingHide the answer
Question ACorrect answer

cyclizine

Marks

2

Explanation

2 marks for ticking the cyclizine and nothing else. Assemble the picture first: two weeks of fluctuating confusion and drowsiness, a dry mouth she waters all day, hard infrequent stools, a resting rate of 96/min and a bladder still palpable after voiding — the peripheral and central signature of antimuscarinic excess. Then read the chart against time. The only prescription started inside the window is cyclizine, added 3 weeks ago for nausea. Its Summary of Product Characteristics (ADVANZ Pharma, revised February 2024) treats it 'as with other anticholinergic agents', warning of precipitated glaucoma and urinary retention, and lists 'Dryness of the mouth, nose and throat', 'Urinary retention' and disorientation among its effects — in a first-generation antihistamine this is expected pharmacology, and in an 84-year-old already on a bladder antimuscarinic it is predictable harm. The infective and metabolic mimics are all closed on paper: apyrexial, CRP 4, glucose, sodium and renal function normal, dipstick negative, TSH 2.1. The habit to take away: every new drug in a confused elderly patient is guilty until proved otherwise, and sedating antihistamines head the list.

Question BCorrect answer

tolterodine

Marks

2

Explanation

2 marks for ticking the tolterodine and nothing else. Anticholinergic burden is cumulative, and the question asks for the drug that set the baseline. Tolterodine is a bladder antimuscarinic: dry mouth is its commonest effect (35% against 10% with placebo in its SmPC), and confusion, hallucinations, disorientation and memory impairment are all reported reactions. Its Summary of Product Characteristics (Detrusitol, Viatris, revised January 2026) states the additive rule in terms: 'Concomitant medication with other drugs that possess antimuscarinic properties may result in more pronounced therapeutic effect and side-effects.' Four years of trouble-free use does not acquit it — it means she was compensating until a second antimuscarinic arrived. No other row competes: amlodipine, atorvastatin, paracetamol and senna have no antimuscarinic pharmacology in their SmPCs, and levothyroxine is closed by the in-range TSH. The management follows from the two ticks: stop the cyclizine, and review whether the tolterodine is still earning its place — in the frail elderly it usually is not.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question REV-83 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Prescription Review · REV-84 · 4 marksA 74-year-old with recurrent hypoglycaemia in general practiceQuestion A: Select the ONE prescription most likely to be causing his hypoglycaemic episodes. (mark it with a tick in column A) Question B: Select the ONE prescription most likely to be masking the warning symptoms of the episodes.

Prescription Review · REV-84 · 4 marks · medium

Case

A 74-year-old man is reviewed urgently in general practice after his wife found him pale, sweating and confused in the garden mid-morning; paramedics recorded a capillary glucose of 2.6 mmol/L and he recovered fully with oral glucose. A near-identical episode happened 3 weeks ago. On neither occasion did he notice palpitations, tremor or hunger beforehand. He has had type 2 diabetes for 12 years. Two months ago his glimepiride was increased after a raised HbA1c, and 6 weeks ago propranolol was restarted for the return of his long-standing migraine. He eats breakfast at seven and takes his morning tablets with it. His current prescriptions are shown.

PMH: Type 2 diabetes mellitus; hypertension; migraine; hypercholesterolaemia; gastro-oesophageal reflux disease; osteoarthritis of the hips.

DH: As charted; no over-the-counter or herbal preparations; no known drug allergies.

SH: Retired postman; lives with his wife; drinks 4 units of alcohol a week; ex-smoker.

On examination: Temperature 36.7°C, HR 58/min regular, BP 134/78 mmHg, RR 14/min, O2 sat 97% breathing air. Weight 71 kg. Alert and fully orientated at review. Cardiovascular, respiratory and abdominal examinations normal. No focal neurology.

Investigations: Capillary glucose during this morning's episode 2.6 mmol/L (4.0–7.8) HbA1c 44 mmol/mol (target 53), and 58 mmol/mol 3 months ago Na 140 mmol/L (133–146) K 4.4 mmol/L (3.5–5.3) Urea 6.8 mmol/L (2.5–7.8) Cr 88 µmol/L (60–120) eGFR 79 mL/min/1.73 m² (>60) ALT 22 U/L (<40)

Question

Question A: Select the ONE prescription most likely to be causing his hypoglycaemic episodes. (mark it with a tick in column A)

Question B: Select the ONE prescription most likely to be masking the warning symptoms of the episodes.

(mark it with a tick in column B)

Current prescriptions

  • amlodipine
  • atorvastatin
  • glimepiride
  • lansoprazole
  • metformin
  • paracetamol
  • propranolol

Tick one prescription in each column: A, B.

Show the answer and markingHide the answer
Question ACorrect answer

glimepiride

Marks

2

Explanation

2 marks for ticking the glimepiride and nothing else. Only one drug on this chart makes insulin: glimepiride, a sulfonylurea that stimulates secretion regardless of the prevailing glucose, which is why its SmPC (Brown & Burk, revised December 2020) builds its central warnings around hypoglycaemia. The chart tells the story in numbers: the dose was doubled to 4 mg two months ago, the HbA1c has fallen from 58 to 44 mmol/mol — well through the target of 53 — and two mid-morning collapses at a capillary glucose of 2.6 mmol/L have followed the morning dose. That is over-treatment in a 74-year-old, in whom the honest correction is a dose reduction, not just a snack. Do not tick the metformin: its own SmPC closes it in one sentence — 'It does not stimulate insulin secretion and therefore does not cause hypoglycaemia.' The remaining rows have no glycaemic pharmacology at all, and the printed eGFR of 79 removes renal accumulation as a competing mechanism. The rule that transfers: when a diabetic chart produces a low glucose, find the secretagogue (or the insulin) first, and ask what changed and when.

Question BCorrect answer

propranolol

Marks

2

Explanation

2 marks for ticking the propranolol and nothing else. The clue is what is missing: on neither occasion did he feel palpitations, tremor or hunger before the collapse. Those early warnings are adrenergic — driven by the catecholamine surge of counter-regulation — and a non-selective beta-blocker sits directly on top of them. Propranolol's SmPC (Amarox, revised April 2026) says so twice: it 'may block/modify the signs and symptoms of the hypoglycaemia (especially tachycardia)' and it 'modifies the tachycardia of hypoglycaemia', with the explicit instruction that 'Caution must be exercised in the concurrent use of propranolol and hypoglycaemic therapy in diabetic patients.' The glimepiride SmPC states the same interaction from the other side: under beta-blockers 'the signs of adrenergic counter regulation to hypoglycaemia may be reduced or absent.' Restarted 6 weeks ago for migraine, propranolol is the only sympatholytic row on the chart — nothing else has adrenergic pharmacology to lose. The practical lesson: in a patient on a sulfonylurea or insulin who needs a beta-blocker, a cardioselective agent is the safer habit, and any beta-blocker demands a warning that hypoglycaemia may now announce itself only as sweating or confusion.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question REV-84 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Prescription Review · REV-80 · 4 marksA 71-year-old with six months of ankle swelling at a medication reviewQuestion A: Select the ONE prescription that has caused the problem for which another medicine on this list was later started. (mark it with a tick in column A) Question B: Select the ONE prescription that was started only to treat an adverse effect of another medicine on this list.

Prescription Review · REV-80 · 4 marks · medium

Case

A 71-year-old woman attends her general practice for her annual medication review. Her ankles have been swollen for the past six months; they were recorded as normal at every previous review, including her last, nine months ago. She has not been breathless. She takes everything as prescribed except the naproxen, taken only during a flare and not taken for 5 weeks.

PMH: Type 2 diabetes of ten years, with painful peripheral neuropathy; hypertension; osteoarthritis of the right shoulder; primary hypothyroidism; vitamin D insufficiency.

DH: Her repeat prescriptions are listed (right); no known drug allergies. The amlodipine and the atorvastatin are unchanged for seven years, the levothyroxine and the metformin older still, the colecalciferol five years. The naproxen, for her shoulder, and the lansoprazole, for gastric protection while she takes it, were started together on the same day, a little over nine months ago — a week before the review at which her ankles were normal. The pregabalin was started for the neuropathy three weeks before the ankles swelled. The furosemide was added six days after the swelling appeared, with 'ankle swelling' written as its indication.

SH: Retired; lives with her husband.

On examination: HR 74/min, BP 132/78 mmHg. Weight 68 kg, unchanged from the day the furosemide was started. Painless pitting oedema to mid-shin, equal on the two sides; no varicose veins. Jugular venous pressure not raised; heart sounds normal; chest clear. No hepatomegaly and no ascites. Reduced pinprick sensation to mid-calf on both sides.

Investigations: Hb 131 g/L (120–150) MCV 89 fL (80–100) K⁺ 3.6 mmol/L (3.5–5.3) eGFR 75 mL/min/1.73 m² (>60) Albumin 41 g/L (35–50) TSH 2.4 mU/L (0.4–4.0) Vitamin B12 421 ng/L (180–900) Urine dipstick: negative for protein and blood

Question

Question A: Select the ONE prescription that has caused the problem for which another medicine on this list was later started. (mark it with a tick in column A)

Question B: Select the ONE prescription that was started only to treat an adverse effect of another medicine on this list.

(mark it with a tick in column B)

Repeat prescriptions

  • amlodipine
  • atorvastatin
  • colecalciferol
  • furosemide
  • lansoprazole
  • levothyroxine sodium
  • metformin hydrochloride
  • naproxen
  • pregabalin

Tick one prescription in each column: A, B.

Show the answer and markingHide the answer
Question ACorrect answer

pregabalin

Marks

2

Explanation

2 marks for the correct tick. Do this with a calendar rather than with a list of side effects. The symptom is bilateral pitting ankle oedema. It was absent at a review nine months ago and at every review before that, and it appeared six months ago. Now read the start dates: amlodipine seven years ago, atorvastatin seven years ago, colecalciferol five years ago, levothyroxine fifteen years ago, metformin ten years ago, naproxen and lansoprazole a little over nine months ago — and pregabalin three weeks before the ankles swelled. Only one thing on the page is new enough to be the cause.

That matters because the pharmacology points the other way. Amlodipine is the drug everybody associates with ankle oedema, and rightly: its Summary of Product Characteristics lists oedema as very common and ankle swelling as common, which is a stronger association than pregabalin's 'common'. But amlodipine oedema is dose-related and appears within weeks of starting or of an increase, and this dose has not changed in seven years, during which her ankles were fine and stayed fine for seven years. A very common adverse effect of a drug she has tolerated for seven years is less likely than a common adverse effect of a drug she started three weeks before the symptom. The strength of the association tells you what to think of first; the dates tell you what actually happened.

Rule out the things that are not drugs before you commit, because 'drug-induced' is a diagnosis of exclusion in a 71-year-old with swollen ankles: the jugular venous pressure is not raised, the heart sounds are normal, the chest is clear, the albumin is 41 g/L, the urine has no protein, the estimated glomerular filtration rate is 75 mL/min/1.73 m², the thyroid-stimulating hormone is normal and there is no hepatomegaly, no ascites and no varicose veins. Do not tick the naproxen: she has taken none for 5 weeks and her ankles were normal for about three months after it was started. The action is to review the pregabalin — reduce it or change the neuropathic agent, and reassess the ankles in a month.

Question BCorrect answer

furosemide

Marks

2

Explanation

2 marks for the correct tick. The furosemide was started six days after the swelling appeared and four weeks after the drug that caused it, and its indication is written on the list as 'ankle swelling' — a symptom, not a diagnosis. That is what a cascade prescription looks like: an adverse effect is read as a new problem, and a second medicine is added for it.

Two details tell you it is not working and was never going to. Her weight is 68 kg today and was 68 kg the day it was started, and the ankles are unchanged. Drug-induced peripheral oedema is a capillary and vasodilatory phenomenon at the ankles rather than an excess of total body water, so a loop diuretic has nothing to remove; it simply takes fluid from a normovolaemic woman. And it is not free. Her potassium is 3.6 mmol/L, at the bottom of the range, on a diuretic that lowers it; a loop diuretic in a 71-year-old also brings hypovolaemia, acute kidney injury, urinary urgency and night-time falls. Six months of that has bought nothing.

The row that catches people out is the lansoprazole. It was started because of another medicine — the indication says so — and a quick reader will tick it. It is a COMPANION prescription, not a cascade: it prevents an adverse effect that has not happened, on the instruction of a guideline, in a patient whose age puts her at risk, and it is licensed for precisely that ('Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk', 15 mg once daily). Look at the dates as well as the words: the lansoprazole and the naproxen were both started on the same day, a little over nine months ago, because they were written together. A cascade drug always comes later, because it is a response to something that happened after the first drug was started. Getting this the wrong way round has a cost in both directions — leaving an at-risk patient on a non-steroidal anti-inflammatory drug without gastroprotection is a defect, and stopping the gastroprotection because it looked like a cascade would create one.

The pregabalin cannot be ticked here, and it is worth knowing why properly rather than by reflex. It would be the right answer if something on this list had caused the neuropathy it treats, and there is a row with a real claim: metformin, taken for ten years, causes vitamin B12 malabsorption, and B12 deficiency causes a peripheral neuropathy. That would be a complete second cascade — metformin, deficiency, neuropathy, pregabalin — and it is the kind of thing this section exists to teach you to look for. Look, then: vitamin B12 421 ng/L (180–900), haemoglobin 131 g/L, mean cell volume 89 fL. All normal, so there is no deficiency and no cascade. What caused her neuropathy is her diabetes, and a disease is not an adverse effect. Do the two things in order — stop the furosemide, and review the drug that made the ankles swell — and check her ankles, her weight, her renal function and her potassium in a month.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question REV-80 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Planning Management · MAN-20 · 2 marksA 72-year-old with watery diarrhoea a week after co-amoxiclavSelect the most appropriate first-line treatment.

Planning Management · MAN-20 · 2 marks · medium

Case

A 72-year-old woman develops profuse watery diarrhoea 1 week after a course of co-amoxiclav.

PMH: recurrent urinary tract infections.

DH: recent co-amoxiclav (completed), omeprazole 20 mg PO once daily.

On examination: mild abdominal tenderness; afebrile, not shocked.

Investigations: stool toxin testing confirms a first episode of Clostridioides difficile infection; WCC 14 ×10⁹/L (4.0–11.0), creatinine 92 µmol/L (60–110).

Question

Select the most appropriate first-line treatment.

(mark it with a tick)

Management options

  1. intravenous ceftriaxone
  2. loperamide
  3. oral amoxicillin
  4. oral metronidazole
  5. oral vancomycin
Show the answer and markingHide the answer
Correct answer

oral vancomycin

Marks

2

Explanation

Oral vancomycin is first-line for a first episode of C. difficile infection (NICE NG199). Oral fidaxomicin is the second-line choice if vancomycin is ineffective; metronidazole no longer has a first-line role and appears only as intravenous adjunctive treatment, on specialist advice, for refractory or life-threatening infection. Antimotility drugs such as loperamide should be avoided.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question MAN-20 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Planning Management · MAN-88 · 2 marksAntithrombotic treatment four weeks after a stented NSTEMISelect the most appropriate antithrombotic regimen to continue from today.

Planning Management · MAN-88 · 2 marks · hard

Case

A 71-year-old man attends the cardiology clinic 4 weeks after a non-ST-elevation myocardial infarction treated by percutaneous coronary intervention with one drug-eluting stent to the left anterior descending artery. The procedure was uncomplicated, with no arrhythmia or hypotension afterwards, and he has had no further chest pain, no bruising and no bleeding.

PMH: Permanent atrial fibrillation for the past 3 years; hypertension; a Helicobacter pylori-associated duodenal ulcer 12 years ago, eradicated and healed, which never bled; no diabetes; no previous stroke or stent.

DH: apixaban 5 mg PO twice daily (12-hrly) (atrial fibrillation); aspirin 75 mg PO daily (after coronary stent); clopidogrel 75 mg PO daily (after coronary stent); lansoprazole 30 mg PO daily (gastroprotection during combined antithrombotic treatment); bisoprolol 5 mg PO daily; ramipril 5 mg PO daily; atorvastatin 80 mg PO nightly (all three after the infarction). No known drug allergies.

SH: Ex-smoker; drinks 6 units weekly; drives.

On examination: Temperature 36.6°C, HR 72/min and irregularly irregular, BP 128/76 mmHg, RR 14/min, O2 sat 97% breathing air. Weight 88 kg, body mass index 27.9 kg/m². Heart sounds normal, chest clear, no peripheral oedema and no raised jugular venous pressure. No bruising, no purpura and no melaena on rectal examination.

Investigations: Hb 143 g/L (130–175), WCC 6.8 ×10⁹/L (4.0–11.0), platelets 268 ×10⁹/L (150–400) Na⁺ 140 mmol/L (135–145), K⁺ 4.3 mmol/L (3.5–5.3), urea 5.8 mmol/L (2.5–7.0), creatinine 92 µmol/L (60–110), eGFR 77 mL/min/1.73 m² (>60) HbA1c 38 mmol/mol (<42) ALT 26 U/L (<41), bilirubin 11 µmol/L (<21) ECG: atrial fibrillation at 72/min, no ischaemic change

Question

Select the most appropriate antithrombotic regimen to continue from today.

(mark it with a tick)

Management options

  1. continue apixaban 5 mg oral (PO) twice daily (12-hrly), aspirin 75 mg oral (PO) daily and clopidogrel 75 mg oral (PO) daily until 12 months after the stent
  2. stop the apixaban and continue aspirin 75 mg oral (PO) daily with clopidogrel 75 mg oral (PO) daily until 12 months after the stent
  3. stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with clopidogrel 75 mg oral (PO) daily until 12 months after the stent
  4. stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with ticagrelor 90 mg oral (PO) twice daily (12-hrly) until 12 months after the stent
  5. stop the aspirin and the clopidogrel and continue apixaban 5 mg oral (PO) twice daily (12-hrly) alone from today
Show the answer and markingHide the answer
Correct answer

stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with clopidogrel 75 mg oral (PO) daily until 12 months after the stent

Marks

2

Explanation

Correct — stop the aspirin and continue apixaban 5 mg oral (PO) twice daily (12-hrly) with clopidogrel 75 mg oral (PO) daily until 12 months after the stent. NICE NG185 recommendation 1.4.22 gives the regimen in one sentence: 'For people already on anticoagulation who have had PCI, continue anticoagulation and clopidogrel for up to 12 months.' Aspirin is not in that sentence, and recommendation 1.4.21 explains why it is the one that goes: 'long-term continuation of aspirin, clopidogrel and oral anticoagulation (triple therapy) significantly increases bleeding risk.' The 2023 ESC acute coronary syndromes guideline puts a clock on it — anticoagulant plus a single antiplatelet, 'preferably clopidogrel', is 'the default strategy for up to 12 months after up to 1 week' of triple therapy — and he is 4 weeks out, so the aspirin is already overdue for withdrawal. The dose stays at apixaban 5 mg twice daily: he meets none of the three reduction criteria, being 71 rather than 80 or over, 88 kg rather than 60 kg or less, and having a creatinine of 92 rather than 133 micromol/L or more. The lansoprazole continues alongside, and at 12 months from the stent the clopidogrel stops and the apixaban carries on by itself.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question MAN-88 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Planning Management · MAN-01 · 2 marksFirst-line treatment for stage 2 hypertension in a 48-year-oldSelect the most appropriate first-line antihypertensive.

Planning Management · MAN-01 · 2 marks · easy

Case

A 48-year-old man of white British family origin attends to discuss blood pressure readings taken at home.

PMH: nil of note; non-smoker.

DH: no regular medication; no allergies.

On examination: BMI 27 kg/m². Stage 2 hypertension confirmed on ambulatory monitoring (average 152/96 mmHg). No end-organ signs.

Investigations: Na 140 mmol/L (135–145), K 4.3 mmol/L (3.5–5.0), creatinine 84 µmol/L (60–110), eGFR >90 mL/min/1.73m², urine ACR normal, HbA1c 38 mmol/mol.

Question

Select the most appropriate first-line antihypertensive.

(mark it with a tick)

Management options

  1. amlodipine
  2. atenolol
  3. bendroflumethiazide
  4. doxazosin
  5. ramipril
Show the answer and markingHide the answer
Correct answer

ramipril

Marks

2

Explanation

For a patient aged under 55 and not of African or Caribbean family origin, NICE recommends an ACE inhibitor (or ARB) first-line. Ramipril is therefore most appropriate; a calcium-channel blocker such as amlodipine would be first-line if he were 55 or over, or of African/Caribbean origin.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question MAN-01 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Communicating Information · COM-03 · 2 marksWhat to tell a 60-year-old starting a weekly bisphosphonateSelect the most important instruction for taking this medicine.

Communicating Information · COM-03 · 2 marks · medium

Case

A 60-year-old woman is started on an oral bisphosphonate for osteoporosis.

PMH: osteoporosis (T-score −2.6), gastro-oesophageal reflux disease.

DH: alendronic acid 70 mg PO once weekly (newly started), colecalciferol.

On examination: no dysphagia.

Investigations: corrected calcium 2.35 mmol/L (2.20–2.60), vitamin D replete.

Question

Select the most important instruction for taking this medicine.

(mark it with a tick)

Information options

  1. crush the tablet into a hot drink if it is hard to swallow whole
  2. take it in the middle of breakfast each week to avoid feeling sick
  3. take it last thing at night and stay lying down afterwards
  4. take it on an empty stomach with water, upright for 30 minutes
  5. take it with a large glass of milk to protect the stomach
Show the answer and markingHide the answer
Correct answer

take it on an empty stomach with water, upright for 30 minutes

Marks

2

Explanation

Oral bisphosphonates must be taken on an empty stomach with plenty of water, while sitting or standing upright for at least 30 minutes, to aid absorption and reduce the risk of oesophageal irritation. Two further points belong to this counselling and are commonly missed: calcium and vitamin D supplements, antacids and iron all bind the bisphosphonate in the gut, so they are taken at least 30 minutes after it, never at the same time; and new thigh, hip or groin pain should be reported, because it can rarely be the first sign of an atypical femoral fracture (MHRA Drug Safety Update, atypical femoral fractures with bisphosphonates). Because she has reflux disease, she should also be told to stop the tablet and seek advice if she develops new or worsening heartburn, pain on swallowing or difficulty swallowing.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question COM-03 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Communicating Information · COM-19 · 2 marksA 24-year-old with epilepsy offered a change to sodium valproateSelect the most important information option that should be provided for the patient.

Communicating Information · COM-19 · 2 marks · hard

Case

A 24-year-old woman with epilepsy attends the neurology clinic to discuss her treatment. She continues to have generalised tonic-clonic seizures despite a full dose of her current medicine, and a change to sodium valproate has been suggested.

PMH: generalised tonic-clonic epilepsy.

DH: levetiracetam 1 g PO twice daily (12-hrly); lamotrigine was stopped last year because of a widespread rash.

SH: sexually active with one partner; uses condoms only. Does not smoke.

On examination: well; BP 118/72 mmHg.

Investigations: a urinary pregnancy test today is negative.

Question

Select the most important information option that should be provided for the patient.

(mark it with a tick)

Information options

  1. an annual risk acknowledgement form is not needed once she is established on it
  2. it can be stopped abruptly at any time without risk of further seizures
  3. it is safe to continue in pregnancy provided high-dose folic acid is taken daily
  4. it must not be started unless two specialists agree there is no alternative
  5. it should be taken only when she feels a seizure starting to come on
Show the answer and markingHide the answer
Correct answer

it must not be started unless two specialists agree there is no alternative

Marks

2

Explanation

When deciding the most important information for this patient, start from the regulatory position rather than from the pharmacology. Following the MHRA Drug Safety Update of January 2024, valproate must not be started in any new patient younger than 55 years — female or male — unless two specialists independently consider and document that there is no other effective or tolerated treatment, or that the reproductive risks do not apply. This patient is 24 and of childbearing potential, so the conversation cannot begin with dosing or with side effects: it has to begin with the fact that starting valproate at all requires that second independent specialist opinion, alongside the pregnancy prevention programme, the annual risk acknowledgement form and highly effective contraception. Valproate exposure in utero carries a risk of major congenital malformation of about 11% and of neurodevelopmental disorder in up to 30–40% of children.

The remaining options are all false. Folic acid does not mitigate the malformation risk of valproate — the MHRA has said so explicitly — and valproate is not safe to continue in pregnancy. The annual risk acknowledgement form is not a one-off: it must be completed with a specialist at initiation and at every annual review for as long as treatment continues. Valproate is prophylactic and is taken regularly; it has no role taken at the onset of a seizure. And no antiepileptic is stopped abruptly — sudden withdrawal precipitates seizures and can precipitate status epilepticus, so any withdrawal is tapered under specialist supervision.

Further information: MHRA/CHM advice, 'Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age', January 2024; NICE NG217, Epilepsies in children, young people and adults.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question COM-19 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Calculation Skills · CAL-48 · 2 marksThe volume of intravenous paracetamol for a 22 kg childWhat volume (mL) of the 10 mg/mL solution provides one 15 mg/kg dose?

Calculation Skills · CAL-48 · 2 marks · medium

Case

A 6-year-old boy weighing 22 kg is nil by mouth after open reduction of a forearm fracture and needs regular analgesia. Intravenous paracetamol is prescribed at 15 mg/kg per dose. The preparation available on the ward is a vial of paracetamol 10 mg/mL solution for infusion, and the nurse asks what volume to draw up for one dose.

Calculation

What volume (mL) of the 10 mg/mL solution provides one 15 mg/kg dose?

(write your answer in the box provided)

Your answer: one number, in mL.

Show the answer and markingHide the answer
Correct answer

33 mL

Marks

2

Explanation

Step 1: dose = 15 mg/kg × 22 kg = 330 mg. Step 2: volume = 330 mg ÷ 10 mg/mL = 33 mL.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question CAL-48 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Calculation Skills · CAL-62 · 2 marksA body-surface-area chemotherapy dose in early breast cancerWhat dose (mg) of doxorubicin hydrochloride should be prescribed for this cycle?

Calculation Skills · CAL-62 · 2 marks · hard

Case

A 54-year-old woman attends the chemotherapy day unit for the first cycle of AC chemotherapy for early breast cancer. She is to be given doxorubicin hydrochloride 60 mg/m² by intravenous injection, followed by cyclophosphamide 600 mg/m² by intravenous infusion, with the cycle repeated every 21 days.

Her height is 1.62 m and her weight is 72 kg. Her body surface area is to be calculated from the formula printed on the day unit's prescribing worksheet:

body surface area (m²) = √(height (cm) × weight (kg) ÷ 3600)

Calculation

What dose (mg) of doxorubicin hydrochloride should be prescribed for this cycle?

(write your answer in the box provided)

Your answer: one number, in mg.

Show the answer and markingHide the answer
Correct answer

108 mg

Marks

2

Explanation

Step 1: height in centimetres = 1.62 m × 100 = 162 cm. Step 2: 162 cm × 72 kg = 11 664, and 11 664 ÷ 3600 = 3.24. Step 3: body surface area = √3.24 = 1.8 m². Step 4: dose = 60 mg/m² × 1.8 m² = 108 mg. The figures resolve exactly, so no rounding instruction is given and the answer is marked all-or-nothing. Omitting the square root gives 194.4 mg and scores zero; entering the height as 1.62 rather than 162 gives 10.8 mg and scores zero; 1080 mg is the cyclophosphamide dose, not the doxorubicin dose.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question CAL-62 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Adverse Drug Reactions · ADR-09 · 2 marksA 62-year-old on amiodarone who feels tired, cold and constipatedSelect the adverse effect most characteristically associated with long-term use of this antiarrhythmic.

Adverse Drug Reactions · ADR-09 · 2 marks · easy

Case

A 62-year-old woman with atrial fibrillation attends for routine review. She has taken the same antiarrhythmic for several months and reports feeling increasingly tired, cold and constipated.

PMH: atrial fibrillation, hypertension.

DH: amiodarone 200 mg PO once daily, apixaban 5 mg PO twice daily, ramipril 5 mg PO once daily.

On examination: HR 58/min, dry skin, slow-relaxing reflexes.

Investigations: TSH 12 mU/L (0.4–4.0), free T4 8 pmol/L (10.0–22.0).

Question

Select the adverse effect most characteristically associated with long-term use of this antiarrhythmic.

(mark it with a tick)

Adverse effect options

  1. gingival hyperplasia
  2. hypothyroidism
  3. nephrotoxicity
  4. pancreatitis
  5. peripheral oedema
Show the answer and markingHide the answer
Correct answer

hypothyroidism

Marks

2

Explanation

Amiodarone commonly causes thyroid dysfunction (both hypo- and hyperthyroidism) because of its high iodine content; the raised TSH with low free T4 here indicates hypothyroidism. It also causes pulmonary, hepatic, corneal and skin effects, so thyroid and liver function are monitored.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question ADR-09 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Adverse Drug Reactions · ADR-89 · 2 marksA 61-year-old with fever, sore eyes, a painful mouth and a spreading rash after an antibioticSelect the medicine most likely to be responsible for this presentation.

Adverse Drug Reactions · ADR-89 · 2 marks · hard

Case

A 61-year-old man attends the emergency department with a painful spreading rash. Five days ago he developed fever, aching, gritty sore eyes and a painful mouth; 2 days ago his general practitioner found an inflamed throat and started an antibiotic. Yesterday tender dusky-red patches appeared on his chest and back and they are now spreading to his arms and thighs, with two areas beginning to blister; swallowing is increasingly painful. Three weeks ago allopurinol was started after his second attack of gout this year.

PMH: gout; chronic kidney disease stage 3; hypertension; dyspepsia.

DH: allopurinol 100 mg PO daily, started 3 weeks ago (gout prophylaxis); amoxicillin 500 mg PO three times daily (8-hrly), started 2 days ago (sore throat); amlodipine 10 mg PO daily (hypertension, 4 years); atorvastatin 20 mg PO nightly (3 years); omeprazole 20 mg PO daily (dyspepsia, 18 months). No known drug allergies.

SH: taxi driver; lives with his wife; drinks 10 units of alcohol a week; non-smoker.

On examination: Temperature 38.4°C, HR 104/min and regular, BP 118/76 mmHg, RR 16/min, O2 sat 97% breathing air. Tender dusky-red macules over the chest, back and proximal limbs, coalescing in places, with two flaccid blisters on the chest, one of which has ruptured to leave a raw erosion; in total about 5% of the body surface is involved. Ulceration of the lips and buccal mucosa; both conjunctivae injected and watering; no genital lesions yet visible. The skin is exquisitely tender to light touch over the affected areas.

Investigations: Hb 142 g/L (130–180), WCC 9.6 ×10⁹/L (4.0–11.0), platelets 234 ×10⁹/L (150–400) Na 136 mmol/L (135–145), K 4.5 mmol/L (3.5–5.3), creatinine 148 µmol/L (60–120) — 141 µmol/L three months ago ALT 66 U/L (10–50), ALP 102 U/L (30–130), bilirubin 12 µmol/L (<21) CRP 74 mg/L (<5); throat swab from the general practice visit: no growth to date

Question

Select the medicine most likely to be responsible for this presentation.

(mark it with a tick)

Prescription options

  1. allopurinol 100 mg PO daily
  2. amlodipine 10 mg PO daily
  3. amoxicillin 500 mg PO three times daily (8-hrly)
  4. atorvastatin 20 mg PO nightly
  5. omeprazole 20 mg PO daily
Show the answer and markingHide the answer
Correct answer

allopurinol 100 mg PO daily

Marks

2

Explanation

The presentation is an evolving severe cutaneous drug reaction — tender dusky macules coalescing and beginning to blister, mucositis at two sites (mouth and eyes), fever, skin pain out of proportion to appearance — and the question is not what it is but who did it. Attribution in severe cutaneous reactions is a timeline exercise, and this chart has three timelines. The background drugs (amlodipine 4 years, atorvastatin 3 years, omeprazole 18 months) are outside any sensitisation window: reactions of this class concentrate in new exposures. The amoxicillin, 2 days old, is the reflex answer — and the printed dates acquit it: the fever, gritty eyes and painful mouth it was prescribed for began 5 days ago, 3 days before its first dose. That 'pharyngitis' was the reaction's own mucosal prodrome, and the throat swab has grown nothing. A drug cannot cause an illness that predates it.

That leaves the allopurinol, started 3 weeks ago — and 3 weeks is exactly where allopurinol hypersensitivity lives. Its Summary of Product Characteristics states: 'The highest risk for SJS and TEN, or other serious hypersensitivity reactions, is within the first weeks of treatment' (Zyloric 100 mg SmPC, section 4.4, read 22 August 2026). His chronic kidney disease raises the risk further — the same section notes chronic kidney disease as an additional risk factor, and the BNF's renal-impairment text for allopurinol warns of an 'Increased risk of hypersensitivity skin reactions'. The correctly cautious 100 mg starting dose does not remove the risk; it is why the dose was 100 mg.

The instruction that follows attribution is absolute: 'allopurinol should be withdrawn immediately and permanently' (same SmPC section) — and the amoxicillin would sensibly stop too pending review, but the marked decision is who is responsible, and it is the drug started 3 weeks ago, not 2 days ago.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question ADR-89 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Drug Monitoring · TDM-18 · 2 marksA 45-year-old on azathioprine for Crohn's disease in remissionSelect the test most important to monitor regularly because of a serious haematological risk.

Drug Monitoring · TDM-18 · 2 marks · easy

Case

A 45-year-old woman attends the gastroenterology clinic for review of the maintenance treatment for her inflammatory bowel disease, which has been in remission for a year. She reports no sore throat, fever, mouth ulcers or unusual bruising.

PMH: Crohn's disease.

DH: azathioprine 100 mg PO daily.

SH: non-smoker.

On examination: temperature 36.7°C, HR 74/min regular, BP 120/74 mmHg; abdomen soft and non-tender.

Investigations: TPMT activity normal before starting; last Hb 128 g/L (115–165), WCC 5.6 ×10⁹/L (4.0–11.0), platelets 240 ×10⁹/L (150–400). Regular blood monitoring is required while treatment continues.

Question

Select the test most important to monitor regularly because of a serious haematological risk.

(mark it with a tick)

Monitoring options

  1. full blood count and differential
  2. serum calcium and phosphate
  3. thiopurine methyltransferase activity
  4. thyroid function tests and cortisol
  5. vitamin B12 and folate levels
Show the answer and markingHide the answer
Correct answer

full blood count and differential

Marks

2

Explanation

Azathioprine can cause bone marrow suppression, so the full blood count is monitored (and thiopurine methyltransferase activity is checked before starting). Allopurinol markedly increases azathioprine toxicity.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question TDM-18 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Drug Monitoring · TDM-88 · 2 marksAn 84-year-old on apixaban reviewed after four days of vomiting and diarrhoeaSelect the most appropriate monitoring option for the apixaban prescription at this review.

Drug Monitoring · TDM-88 · 2 marks · hard

Case

An 84-year-old woman attends her general practice 2 days after a diarrhoeal illness settled. During a norovirus outbreak at her sheltered housing scheme she had 4 days of vomiting and watery diarrhoea, managed at home; she is now eating again but still feels washed out. She took all her tablets throughout, including on the days she could keep little else down. Her next anticoagulation review, with blood tests, is booked in 6 weeks.

PMH: atrial fibrillation; hypertension; chronic kidney disease.

DH: apixaban 2.5 mg PO twice daily (12-hrly) (atrial fibrillation); ramipril 2.5 mg PO daily (hypertension); amlodipine 5 mg PO daily (hypertension); paracetamol 1 g PO 6-hrly as required. No known drug allergies.

SH: widowed; lives alone in sheltered housing; lifelong non-smoker; no alcohol.

On examination: Temperature 36.6°C, HR 78/min and irregularly irregular, RR 14/min, O2 sat 97% breathing air. BP 126/74 mmHg sitting, 108/66 mmHg after 1 minute standing, with light-headedness on standing. Weight 56 kg, recorded 58 kg at her last review. Dry lips; abdomen soft and non-tender; no bruising and no bleeding.

Investigations: At her last anticoagulation review 6 weeks ago: Na 138 mmol/L (135–145), K 4.6 mmol/L (3.5–5.3), creatinine 110 µmol/L (45–84), eGFR 43 mL/min/1.73 m² (>60); creatinine clearance 31 mL/min by the Cockcroft–Gault equation at her then weight of 58 kg Hb at that review 121 g/L (115–165); no blood tests have been taken since

Question

Select the most appropriate monitoring option for the apixaban prescription at this review.

(mark it with a tick)

Monitoring options

  1. anti-factor Xa activity, before the next apixaban dose
  2. creatinine clearance (Cockcroft–Gault), at the booked review in 6 weeks
  3. creatinine clearance (Cockcroft–Gault), recalculated today
  4. international normalised ratio, today
  5. no blood monitoring at any stage of treatment
Show the answer and markingHide the answer
Correct answer

creatinine clearance (Cockcroft–Gault), recalculated today

Marks

2

Explanation

Two separate pieces of knowledge are being marked. The first is which parameter follows a direct oral anticoagulant: not the INR (BNF, apixaban, Monitoring requirements: 'No routine anticoagulant monitoring required (INR tests are unreliable)', read 22 August 2026), not a routine anti-factor Xa level — the drug has no target range to titrate to — but the kidney function that determines its dose and its licence. Apixaban is avoided below a creatinine clearance of 15 mL/minute and dose-reduced at 15–29 mL/minute, and the clearance is calculated by Cockcroft–Gault, not read off an eGFR.

The second is when. Her stable-state schedule is genuinely the booked one: NICE CKS (Anticoagulation — oral, apixaban scenario, last revised April 2026, read 22 August 2026) repeats the bloods yearly for most people, every 4 months over 75, and by 'CrCl divided by 10' months below 60 mL/minute — about every 3 months at her 31 mL/min. The check booked in 6 weeks respects all of that. What overrides it is the same page's event clause: 'If the person has an intercurrent illness that may impact renal or hepatic function, repeat renal and liver function tests as needed.' Four days of vomiting and diarrhoea, a 2 kg weight loss, a postural blood pressure drop and a continued ACE inhibitor, in a woman whose clearance already sits 2 mL/min above the 15–29 mL/minute band, is exactly the illness that clause describes. If today's clearance has fallen below 15 mL/minute, she is taking a drug she should not be taking at all — and nobody would know until the booked bloods in 6 weeks.

The wrong answers each carry a real fact one step too far: anti-factor Xa assays exist but are reserved for exceptional situations, not reviews; the booked interval is correct arithmetic applied to a schedule the illness has suspended; the INR belongs to her neighbour on warfarin; and 'no monitoring' over-reads the no-INR-clinic message into a claim the dosing criteria on her own chart refute.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question TDM-88 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Data Interpretation · DAT-51 · 2 marksAn 81-year-old drowsy on morphine three days after a hip hemiarthroplastySelect the most appropriate decision option with regard to his morphine sulfate prescription based on these data.

Data Interpretation · DAT-51 · 2 marks · hard

Case

An 81-year-old man is reviewed on the orthopaedic ward 3 days after a hemiarthroplasty for a fractured neck of femur. Nursing staff report that he has become increasingly drowsy overnight and needed waking for his morning observations, although he answers questions when roused. His hip pain has been well controlled. He has eaten and drunk very little since surgery.

PMH: Hypertension; osteoarthritis; benign prostatic hyperplasia.

DH: Morphine sulfate m/r 20 mg PO twice daily (12-hrly) and morphine sulfate oral solution 5 mg PO as required (both started after surgery), paracetamol 1 g PO four times daily (6-hrly), senna 15 mg PO nightly, ramipril 5 mg PO daily, amlodipine 5 mg PO daily, tamsulosin hydrochloride 400 micrograms PO daily. No known drug allergies.

SH: Lives alone; independent before the fall; lifelong non-smoker. His ramipril has been withheld since yesterday and intravenous fluids have been started.

On examination: Temperature 36.6°C, HR 84/min and rhythm regular, BP 112/68 mmHg, RR 11/min, O₂ sat 95% breathing air. Drowsy but rousable to voice; pupils small but reactive; occasional myoclonic jerks of both hands. Chest clear. Wound clean and dry. Abdomen soft; bladder not palpable. The observation chart shows RR 18/min on the evening of surgery 3 days ago, 14/min yesterday evening and 11/min at 06.00 h today.

Investigations: Hb 103 g/L (130–170) WCC 9.6 ×10⁹/L (3.0–10.0) Platelets 318 ×10⁹/L (150–400) Na⁺ 141 mmol/L (137–144) K⁺ 5.1 mmol/L (3.5–5.3) U 5.6 mmol/L (2.5–7.0) on admission; 15.8 today. Cr 88 µmol/L (60–110) on admission 3 days ago; 141 yesterday; 196 today. eGFR 74 mL/min/1.73 m² (>60) on admission; 29 today. CRP 58 mg/L (<5)

Question

Select the most appropriate decision option with regard to his morphine sulfate prescription based on these data.

(mark it with a tick)

Decision options

  1. apply a fentanyl transdermal patch and stop morphine
  2. continue morphine at the current dose with hourly observations
  3. give naloxone immediately and stop all opioid analgesia
  4. halve the dose of morphine and continue at the same frequency
  5. stop morphine and prescribe oxycodone when the next dose of analgesia is due
Show the answer and markingHide the answer
Correct answer

stop morphine and prescribe oxycodone when the next dose of analgesia is due

Marks

2

Explanation

Correct answer: stop morphine and prescribe oxycodone when the next dose of analgesia is due. The serial creatinine (88 → 141 → 196 µmol/L) shows a worsening AKI, and the falling respiratory rate (18 → 14 → 11/min) with drowsiness, small pupils and myoclonus is early toxicity from accumulating morphine-6-glucuronide. Oxycodone is predominantly hepatically metabolised and, at a reduced dose, is the safer titratable replacement (the BNF advises an initial 50% dose reduction and caution in renal impairment, because its effects can still be increased and prolonged); a fentanyl patch is right in principle but too slow and untitratable for acute pain, and naloxone is not yet indicated in a rousable patient with maintained oxygen saturation.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question DAT-51 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Data Interpretation · DAT-75 · 2 marksAn 82-year-old in residential care with three days of confusion and drowsinessSelect the most appropriate decision option based on these data.

Data Interpretation · DAT-75 · 2 marks · medium

Case

An 82-year-old woman is seen at her residential home by the duty general practitioner because staff report 3 days of increasing confusion and daytime drowsiness; she is normally orientated and washes and dresses herself. She has no burning on passing urine, no urinary frequency or urgency, no new incontinence and no suprapubic or loin pain, and the home's observation charts record no fever. She has opened her bowels once in 5 days. A urine specimen sent 2 days ago as part of the home's routine has been reported.

PMH: osteoporosis with a vertebral fracture 3 weeks ago; hypertension; chronic kidney disease.

DH: codeine phosphate 30 mg PO 6-hrly (back pain, started 3 weeks ago), amlodipine 5 mg PO daily (hypertension), alendronic acid 70 mg PO weekly with colecalciferol (osteoporosis). No known drug allergies.

SH: lives in a residential home; does not smoke; drinks no alcohol.

On examination: Temperature 36.7°C, HR 78/min and rhythm regular, BP 128/74 mmHg, RR 16/min, O₂ sat 96% breathing air. Drowsy but rousable, orientated to person only, inattentive; 4AT score 5. No new focal neurological signs. Chest clear. Abdomen soft with palpable faecal loading in the left iliac fossa; no suprapubic tenderness and no renal angle tenderness; bladder not palpable. No catheter. Weight 58 kg.

Investigations: Hb 124 g/L (115–165), WCC 7.8 ×10⁹/L (4.0–11.0), neutrophils 4.9 ×10⁹/L (2.0–7.5), platelets 268 ×10⁹/L (150–400) CRP 4 mg/L (<5) Na⁺ 138 mmol/L (135–145), K⁺ 4.3 mmol/L (3.5–5.3), creatinine 124 µmol/L (45–90), eGFR 37 mL/min/1.73 m² (>60) Corrected Ca²⁺ 2.34 mmol/L (2.20–2.60), capillary blood glucose 6.2 mmol/L (4.0–7.8), TSH 2.4 mU/L (0.4–4.0) Midstream specimen of urine (non-catheter) sent 2 days ago and reported today — microscopy: white cells 60 ×10⁶/L, red cells <10 ×10⁶/L, no epithelial cells seen; culture: Escherichia coli, pure growth >10⁸ colony-forming units/L, sensitive to nitrofurantoin, cefalexin, co-amoxiclav, ciprofloxacin and gentamicin, resistant to amoxicillin and trimethoprim; laboratory comment: pure growth of a single organism, susceptibilities are reported for guidance Chest radiograph the same day: no consolidation

Question

Select the most appropriate decision option based on these data.

(mark it with a tick)

Decision options

  1. admit to hospital for intravenous antibiotics
  2. no antibiotic; investigate other causes of the delirium
  3. start cefalexin 250 mg PO 8-hrly for 7 days
  4. start nitrofurantoin 100 mg modified-release PO 12-hrly for 3 days
  5. start trimethoprim 200 mg PO 12-hrly for 3 days
Show the answer and markingHide the answer
Correct answer

no antibiotic; investigate other causes of the delirium

Marks

2

Explanation

Bacteriuria is common in older people living in care homes and rises further with age and frailty; a positive culture on its own therefore says very little. It becomes a urinary tract infection only when it is accompanied by urinary symptoms — dysuria, new frequency or urgency, new incontinence, suprapubic or loin pain — or by systemic features of infection. This woman has none of them. She is afebrile, her white cell count is 7.8 ×10⁹/L and her C-reactive protein is 4 mg/L. What she has is asymptomatic bacteriuria, and NICE NG109 and NICE QS90 are explicit that antibacterials should not be prescribed for it in men or non-pregnant women, including older people. The white cells seen on microscopy do not change this: pyuria accompanies asymptomatic bacteriuria and is not itself an indication.

She does have delirium — a 4AT score of 5 with acute onset, inattention and drowsiness — and the obligation the culture must not be allowed to displace is to look for its cause. Two candidates are already on the page: codeine phosphate started 3 weeks ago after a vertebral fracture, and constipation with one bowel motion in 5 days and palpable faecal loading. Pain, dehydration, hypoxia, biochemical disturbance and any recent medicine change all belong in the same screen.

Why not the others? Cefalexin is sensitive on the report and the dose offered is already the reduced one for her renal function — her Cockcroft–Gault creatinine clearance is about 28 mL/min at 82 years, 58 kg and a creatinine of 124 µmol/L, and 250 mg 8-hrly sits within the 1.5 g daily maximum the BNF sets for an eGFR of 10–40 mL/min/1.73 m² — but there is no infection to treat, and the course would risk Clostridioides difficile infection and diarrhoea that would worsen the delirium. Nitrofurantoin fails on the same indication argument, and the BNF advises avoiding it below an eGFR of 45 mL/min/1.73 m² (it may be used with caution at 30–44 only as a short course of 3 to 7 days for lower urinary tract infection caused by suspected or proven multidrug-resistant bacteria). Trimethoprim fails twice: the isolate is reported resistant, and trimethoprim raises creatinine and potassium in impaired renal function. Admission for intravenous antibiotics treats a sepsis that the observations and inflammatory markers exclude, and moving a delirious patient out of familiar surroundings usually makes her worse (NICE NG109, 2018, current 2026; NICE QS90 statement 3; NICE CG103 delirium; UKHSA diagnosis of urinary tract infections quick reference tool).

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question DAT-75 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Data Interpretation · DAT-56 · 2 marksVancomycin for Staphylococcus aureus bacteraemia on day three of admissionSelect the most appropriate decision option with regard to the vancomycin prescription based on these data.

Data Interpretation · DAT-56 · 2 marks · medium

Case

A 64-year-old man is reviewed on the acute medical unit on day 3 of an admission with fever and rigors from an infected peripheral cannula site in the left forearm; the cannula was removed on admission. Two sets of blood cultures taken before any antibacterial have grown Staphylococcus aureus, and the laboratory has reported sensitivities. He was started on empirical intravenous vancomycin on admission and has been afebrile for 24 hours, eating and drinking normally.

PMH: Type 2 diabetes mellitus; hypertension.

DH: Vancomycin 1 g IV 12-hrly; metformin hydrochloride 1 g PO twice daily (12-hrly); ramipril 5 mg PO daily. No known drug allergies — he completed a course of amoxicillin last year without reaction.

SH: Non-smoker; retired postal worker. A transthoracic echocardiogram shows no vegetation and he has no prosthetic valve, joint or indwelling line.

On examination: Temperature 36.7°C, HR 84/min and rhythm regular, BP 128/76 mmHg, RR 16/min, O₂ sat 97% breathing air. Left forearm cannula site clean and dry with no residual cellulitis; no new murmur and no peripheral stigmata of endocarditis. Weight 78 kg.

Investigations: Hb 126 g/L (130–170) WCC 11.2 ×10⁹/L (4.0–11.0) (16.8 on admission) Platelets 268 ×10⁹/L (150–400) Na⁺ 138 mmol/L (137–144) K⁺ 4.2 mmol/L (3.5–5.3) U 5.4 mmol/L (2.5–7.0) Cr 82 µmol/L (60–110) eGFR 92 mL/min/1.73 m² (>60) CRP 68 mg/L (<5) (214 on admission) Vancomycin 16.4 mg/L (15–20), pre-dose (trough) level taken immediately before the fifth dose Blood cultures 2 of 2 sets (<24) positive (aerobic and anaerobic bottles), taken on admission before treatment: Staphylococcus aureus — sensitive to flucloxacillin (meticillin), co-amoxiclav, doxycycline, gentamicin, rifampicin, vancomycin and linezolid; resistant to penicillin, amoxicillin, erythromycin and clindamycin; laboratory comment: meticillin-sensitive Staphylococcus aureus (MSSA), beta-lactamase producer, please discuss with microbiology if patient is penicillin allergic Repeat blood cultures 0 of 2 sets (<24) positive, taken at 48 hours: no growth to date

Question

Select the most appropriate decision option with regard to the vancomycin prescription based on these data.

(mark it with a tick)

Decision options

  1. add gentamicin 5 mg/kg IV daily to the vancomycin
  2. continue vancomycin 1 g IV 12-hrly
  3. switch to co-amoxiclav 1.2 g IV 8-hrly
  4. switch to doxycycline 100 mg PO 12-hrly
  5. switch to flucloxacillin 2 g IV 6-hrly
Show the answer and markingHide the answer
Correct answer

switch to flucloxacillin 2 g IV 6-hrly

Marks

2

Explanation

The attached grid reports penicillin R but flucloxacillin (meticillin) S: this is meticillin-sensitive Staphylococcus aureus. At the 48–72 hour antimicrobial review, empirical vancomycin must therefore be de-escalated to the antistaphylococcal penicillin, which is more effective than a glycopeptide against a meticillin-sensitive isolate. With no allergy, normal renal function and an uncomplicated cannula-related bacteraemia, switch to flucloxacillin 2 g IV 6-hrly.

This example on its own page, with the method and checklist →

© 2026 PassthePSA · Question DAT-56 · Free sample for personal study. Copying, republishing or AI training use is not permitted (terms).

Official figures on this page were checked against the official PSA site; the official site is authoritative.

Start practising →